
Arthur L. Corbin
Examiner (ID: 24)
| Most Active Art Unit | 1302 |
| Art Unit(s) | 1794, 1302, 1761 |
| Total Applications | 1985 |
| Issued Applications | 1221 |
| Pending Applications | 190 |
| Abandoned Applications | 573 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17981282
[patent_doc_number] => 20220347318
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => METHODS AND COMPOSITIONS FOR THE EXPRESSION OF CONSTITUTIVELY ACTIVE RAP1A FROM A VMD2 PROMOTER
[patent_app_type] => utility
[patent_app_number] => 17/763767
[patent_app_country] => US
[patent_app_date] => 2020-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15746
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763767
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/763767 | METHODS AND COMPOSITIONS FOR THE EXPRESSION OF CONSTITUTIVELY ACTIVE RAP1A FROM A VMD2 PROMOTER | Sep 24, 2020 | Pending |
Array
(
[id] => 16711921
[patent_doc_number] => 20210079068
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => ANTIBODY GENE THERAPY FOR TREATMENT AND PREVENTION OF INFECTION BY RABIES LYSSAVIRUS
[patent_app_type] => utility
[patent_app_number] => 17/024424
[patent_app_country] => US
[patent_app_date] => 2020-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15467
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17024424
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/024424 | ANTIBODY GENE THERAPY FOR TREATMENT AND PREVENTION OF INFECTION BY RABIES LYSSAVIRUS | Sep 16, 2020 | Abandoned |
Array
(
[id] => 16726521
[patent_doc_number] => 20210093668
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => NUCLEIC ACID CONSTRUCTS COMPRISING GENE EDITING MULTI-SITES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/021526
[patent_app_country] => US
[patent_app_date] => 2020-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 64832
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17021526
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/021526 | NUCLEIC ACID CONSTRUCTS COMPRISING GENE EDITING MULTI-SITES AND USES THEREOF | Sep 14, 2020 | Abandoned |
Array
(
[id] => 17881167
[patent_doc_number] => 20220296644
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-22
[patent_title] => CHIMERIC ORTHOGONAL RECEPTOR PROTEINS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/641688
[patent_app_country] => US
[patent_app_date] => 2020-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21036
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17641688
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/641688 | CHIMERIC ORTHOGONAL RECEPTOR PROTEINS AND METHODS OF USE | Sep 9, 2020 | Pending |
Array
(
[id] => 16686773
[patent_doc_number] => 20210069248
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
[patent_app_type] => utility
[patent_app_number] => 17/017670
[patent_app_country] => US
[patent_app_date] => 2020-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35720
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17017670
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/017670 | CA2 compositions and methods for tunable regulation | Sep 9, 2020 | Issued |
Array
(
[id] => 17007097
[patent_doc_number] => 20210238258
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => CHIMERIC ORTHOGONAL RECEPTOR PROTEINS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/017522
[patent_app_country] => US
[patent_app_date] => 2020-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21678
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17017522
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/017522 | CHIMERIC ORTHOGONAL RECEPTOR PROTEINS AND METHODS OF USE | Sep 9, 2020 | Abandoned |
Array
(
[id] => 16885396
[patent_doc_number] => 20210171591
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => CODON OPTIMIZED NUCLEIC ACID ENCODING A RETINITIS PIGMENTOSA GTPASE REGULATOR (RPGR)
[patent_app_type] => utility
[patent_app_number] => 17/016312
[patent_app_country] => US
[patent_app_date] => 2020-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5281
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17016312
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/016312 | CODON OPTIMIZED NUCLEIC ACID ENCODING A RETINITIS PIGMENTOSA GTPASE REGULATOR (RPGR) | Sep 8, 2020 | Abandoned |
Array
(
[id] => 16791763
[patent_doc_number] => 20210121580
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-29
[patent_title] => Functionalized DNA Dendrimers For Gene Delivery To Cells
[patent_app_type] => utility
[patent_app_number] => 17/015925
[patent_app_country] => US
[patent_app_date] => 2020-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8952
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17015925
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/015925 | Functionalized DNA Dendrimers For Gene Delivery To Cells | Sep 8, 2020 | Abandoned |
Array
(
[id] => 16656012
[patent_doc_number] => 20210052648
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => METHOD OF PRODUCING LEUKOCYTES USING PTPN2 INHIBITION FOR ADOPTIVE CELL TRANSFER
[patent_app_type] => utility
[patent_app_number] => 17/014737
[patent_app_country] => US
[patent_app_date] => 2020-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18232
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17014737
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/014737 | METHOD OF PRODUCING LEUKOCYTES USING PTPN2 INHIBITION FOR ADOPTIVE CELL TRANSFER | Sep 7, 2020 | Abandoned |
Array
(
[id] => 16484265
[patent_doc_number] => 20200377866
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-03
[patent_title] => COMPOSITIONS USEFUL IN TREATMENT OF ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY
[patent_app_type] => utility
[patent_app_number] => 16/995572
[patent_app_country] => US
[patent_app_date] => 2020-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14232
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16995572
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/995572 | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency | Aug 16, 2020 | Issued |
Array
(
[id] => 16686872
[patent_doc_number] => 20210069347
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => GENE AUGMENTATION THERAPIES FOR INHERITED RETINAL DEGENERATION CAUSED BY MUTATIONS IN THE PRPF31 GENE
[patent_app_type] => utility
[patent_app_number] => 16/992689
[patent_app_country] => US
[patent_app_date] => 2020-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15336
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16992689
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/992689 | GENE AUGMENTATION THERAPIES FOR INHERITED RETINAL DEGENERATION CAUSED BY MUTATIONS IN THE PRPF31 GENE | Aug 12, 2020 | Abandoned |
Array
(
[id] => 19778519
[patent_doc_number] => 12227543
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-18
[patent_title] => Ancestral virus sequences and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/989454
[patent_app_country] => US
[patent_app_date] => 2020-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 51
[patent_no_of_words] => 21247
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989454
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/989454 | Ancestral virus sequences and uses thereof | Aug 9, 2020 | Issued |
Array
(
[id] => 16570649
[patent_doc_number] => 20210009655
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTOR ADAPTERS
[patent_app_type] => utility
[patent_app_number] => 16/983977
[patent_app_country] => US
[patent_app_date] => 2020-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44822
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16983977
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/983977 | METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTOR ADAPTERS | Aug 2, 2020 | Abandoned |
Array
(
[id] => 16671320
[patent_doc_number] => 20210060083
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-04
[patent_title] => METHODS FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/925276
[patent_app_country] => US
[patent_app_date] => 2020-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10813
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16925276
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/925276 | METHODS FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOF | Jul 8, 2020 | Abandoned |
Array
(
[id] => 16571000
[patent_doc_number] => 20210010006
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => INCREASED NUCLEIC ACID-GUIDED CELL EDITING VIA A LEXA-RAD51 FUSION PROTEIN
[patent_app_type] => utility
[patent_app_number] => 16/917905
[patent_app_country] => US
[patent_app_date] => 2020-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25804
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16917905
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/917905 | INCREASED NUCLEIC ACID-GUIDED CELL EDITING VIA A LEXA-RAD51 FUSION PROTEIN | Jun 30, 2020 | Abandoned |
Array
(
[id] => 20414358
[patent_doc_number] => 12497631
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-16
[patent_title] => Use of microvesicles in the treatment of medical conditions
[patent_app_type] => utility
[patent_app_number] => 16/909420
[patent_app_country] => US
[patent_app_date] => 2020-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 11
[patent_no_of_words] => 5948
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16909420
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/909420 | Use of microvesicles in the treatment of medical conditions | Jun 22, 2020 | Issued |
Array
(
[id] => 18733554
[patent_doc_number] => 11802277
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-31
[patent_title] => Thermostable Cas9 nucleases
[patent_app_type] => utility
[patent_app_number] => 16/906741
[patent_app_country] => US
[patent_app_date] => 2020-06-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 5
[patent_no_of_words] => 13539
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16906741
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/906741 | Thermostable Cas9 nucleases | Jun 18, 2020 | Issued |
Array
(
[id] => 16341663
[patent_doc_number] => 20200306313
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => METHODS AND COMPOSITIONS FOR NON-CYTOTOXIC STEM CELL TRANSPLANTATION
[patent_app_type] => utility
[patent_app_number] => 16/900178
[patent_app_country] => US
[patent_app_date] => 2020-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14512
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 119
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16900178
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/900178 | METHODS AND COMPOSITIONS FOR NON-CYTOTOXIC STEM CELL TRANSPLANTATION | Jun 11, 2020 | Abandoned |
Array
(
[id] => 17828559
[patent_doc_number] => 20220265863
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF DBA USING GATA1 GENE THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/612465
[patent_app_country] => US
[patent_app_date] => 2020-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33888
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17612465
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/612465 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DBA USING GATA1 GENE THERAPY | Jun 7, 2020 | Pending |
Array
(
[id] => 16310833
[patent_doc_number] => 20200289571
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY
[patent_app_type] => utility
[patent_app_number] => 16/885882
[patent_app_country] => US
[patent_app_date] => 2020-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47905
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16885882
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/885882 | TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY | May 27, 2020 | Abandoned |